Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
J Control Release. 2012 Sep 10;162(2):303-9. doi: 10.1016/j.jconrel.2012.06.030. Epub 2012 Jul 1.
Releasing drug molecules at their targets with high spatial and temporal accuracy could aid numerous clinical applications which require low systemic damage and low side effects. Nano-carriers of drugs are an attractive solution for such task, allowing specific accumulation in tumors and gradual release of their payload. Here, we utilize gold nanospheres conjugated to Rituximab, an anti-CD20 monoclonal antibody-based drug, for carrying and releasing the drug upon irradiation of specifically tailored femtosecond laser pulses. The released anti-CD20 molecules retain their functionality and ability of triggering the complement-dependent cytotoxicity. This effect comes in addition to cell necrosis caused by the plasmonic nanometric shock waves emanating from the nanospheres and rupturing the plasma membranes. Main advantages of the presented technique include high spatial and temporal resolution, low toxicity and high repeatability and consistency due to the morphological stability of the nanospheres.
以高时空精度在靶点释放药物分子,可以帮助许多需要低系统损伤和低副作用的临床应用。药物的纳米载体是实现这一目标的一种有吸引力的解决方案,允许药物在肿瘤中的特异性积累和逐渐释放其有效载荷。在这里,我们利用金纳米球与利妥昔单抗(一种基于抗 CD20 单克隆抗体的药物)结合,用于携带和释放药物,方法是用专门设计的飞秒激光脉冲照射。释放的抗 CD20 分子保留其功能和触发补体依赖性细胞毒性的能力。这种效应除了由纳米球发出的等离子体纳米级冲击波引起的细胞坏死之外,还会出现这种效应,这种冲击波会破坏质膜。所提出的技术的主要优点包括高时空分辨率、低毒性以及由于纳米球的形态稳定性而具有高重复性和一致性。